Login
Companies $CHRS
$0.51 +$0.00 (0.81%) After hours
Coherus Oncology, Inc. logo

Coherus Oncology, Inc.

coherus.com

What Do They Do?

Sells LOQTORZI, a treatment for nasopharyngeal cancer, to hospitals and clinics, and develops antibody candidates for other cancers.

How Do They Make Money?

Coherus sells LOQTORZI to wholesalers and distributors for resale to hospitals and clinics; payment typically follows shipment.

revenue
SegmentShareRevenue
Toripalimab
Sold outright

97%
Other revenue
3.2%
FY2022: 0.1%

Who Are Their Customers?

Coherus sells LOQTORZI to wholesale distributors, which resell it to hospitals and clinics; group purchasing organizations and commercial or government payers are involved in discounts and reimbursement.

Customers above 10% of revenue, FY2025
of revenue from three customers (43%, 36%, 20%)
FY2024: 99% from three customers

Do Revenues Turn Into Profits?

Yes. Its net income in FY2025 was larger than its revenue.

Operating income, FY2025
−430% of revenue
▲ +9% (Loss) vs FY2024 (−$199.7M, −757%)
Net income, FY2025
398% of revenue
▲ +489% vs FY2024 ($28.5M, 108%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▲ +23%
vs $11.6M in Q3 FY2025
Net income
▼ −11% (Loss)
vs −$35.5M in Q3 FY2025
Toripalimab share of revenue vs 96.5% in Q3 FY2025
  • Jun 12, 2026 Coherus dismissed EY and selected PwC as auditor PwC was selected to serve as auditor for fiscal 2026, subject to standard client acceptance procedures.

Shrinking. Revenue fell 87% in 4 years, from $326.6M in FY2021 to $42.2M in FY2025, about 40% a year.

Shift to oncology focus The older report described biosimilars alongside oncology development; the latest describes a business focused on LOQTORZI and immuno-oncology candidates after biosimilar divestitures.

Revenue over time
Toripalimab Other revenue Total net product revenue UDENYCA CIMERLI
$500M$250M$0

Who Do They Compete With?

Competes with Merck, Bristol-Myers Squibb, Genentech, AstraZeneca, EMD Serono, Pfizer, Regeneron Pharmaceuticals, GlaxoSmithKline, BeiGene, Elevar Therapeutics, Jiangsu Hengrui Pharmaceuticals, Akeso, Gilead Sciences, Jounce Therapeutics, Shionogi, AbbVie, Bayer, F. Hoffmann-La Roche, Amgen, and LaNova Medicines

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support